Ensartinib Approved by FDA for First-Line ALK-Positive Non-Small Cell Lung Cancer
• The FDA has approved ensartinib (Ensacove) for first-line treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
• Ensartinib demonstrated statistically significant improvement in progression-free survival compared to crizotinib in the eXALT3 trial.
• Common adverse reactions to ensartinib include rash, musculoskeletal pain, constipation, cough, pruritus, nausea, edema, pyrexia, and fatigue.
• The recommended dose of ensartinib is 225 mg orally once daily until disease progression or unacceptable toxicity.
© Copyright 2025. All Rights Reserved by MedPath